Insights with Goldman Sachs Part 2: How pharma is using M&A for growth and innovation
What’s on the horizon for biopharma M&A? We’ll likely see a lot more M&A in months to come. Investors will help drive innovation in rare disease and oncology, plus other therapeutic areas that have been off the radar. Hear more from Jerry Lee, Partner and Managing Director of Investment Banking at Goldman Sachs.
Disclaimer: The views and opinions that the panelists express are their own and are for informational purposes only. They do not constitute a recommendation by Goldman Sachs Asset Management for you to take any action.